Evidence map›Paper›PMID 38368775›Full record

ArticleThe Journal of surgical research2024

Immune Landscape of Epstein-Barr Virus-Associated Gastric Cancer: Analysis From a Western Academic Institution.

Elliott J Yee, Danielle Gilbert, Jeffrey Kaplan, Linda van Dyk, Sunnie S Kim, Leslie Berg, Eric Clambey, Sachin Wani, Martin D McCarter, Camille L Stewart

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of surgical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Elliott J YeeDivision of Surgical Oncology, Department of Surgery, University of Colorado, Aurora, Colorado. Electronic address: elliott.yee@cuanschutz.edu.
Danielle GilbertSchool of Medicine, University of Colorado, Aurora, Colorado.
Jeffrey KaplanDepartment of Pathology, University of Colorado, Aurora, Colorado.
Linda van DykDepartment of Immunology & Microbiology, University of Colorado, Aurora, Colorado.
Sunnie S KimDivision of Medical Oncology, Department of Medicine, University of Colorado, Aurora, CO.
Leslie BergDepartment of Immunology & Microbiology, University of Colorado, Aurora, Colorado.
Eric ClambeyDepartment of Anesthesiology, University of Colorado, Aurora, Colorado.
Sachin WaniDivision of Medical Oncology, Department of Medicine, University of Colorado, Aurora, CO.
Martin D McCarterDivision of Surgical Oncology, Department of Surgery, University of Colorado, Aurora, Colorado.
Camille L StewartDivision of Surgical Oncology, Department of Surgery, University of Colorado, Aurora, Colorado.
University of Colorado Anschutz Medical Campus · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Tec family tyrosine kinases in T cell signalingR01AI037584 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BERG, LESLIE JOAN · 1995 to 2009
$2.8M
Dissecting the pathways controlling tunable responses to TCR signalingR01AI132419 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BERG, LESLIE JOAN · 2018 to 2022
$2.5M
NCI NIH HHS P30 CA046934NIAID NIH HHS R01 AI037584NIAID NIH HHS R01 AI132419
6 · The paper itself

Abstract

introductionEpstein-Barr virus-associated gastric cancer (EBVaGC) may be a meaningful biomarker for potential benefit from immunotherapy. Further investigation is needed to characterize the immune landscape of EBVaGC. We assessed our institutional frequency of surgically treated EBVaGC and analyzed the immunologic biomarker profile and tumor-infiltrating lymphocyte (TIL) phenotypes of a series of EBVaGC compared to non-EBVaGC cases.

methodsAvailable tissue samples from all patients with biopsy-confirmed gastric adenocarcinoma who underwent resection with curative intent from 2012 to 2020 at our institution were collected. In situ hybridization was used to assess EBV status; multiplex immunohistochemistry was performed to assess mismatch repair status, Programmed Death-Ligand 1 (PD-L1) expression, and phenotypic characterization of TILs.

resultsSixty-eight samples were included in this study. EBVaGC was present in 3/68 (4%) patients. Among all patients, 27/68 (40%) had positive PD-L1 expression; two of three (67%) EBVaGC patients exhibited positive PD-L1 expression. Compared to non-EBVaGC, EBV-positive tumors showed 5-fold to 10-fold higher density of TILs in both tumor and stroma and substantially elevated CD8+ T cell to Tregulatory cell ratio. The memory subtypes of CD8+ and CD4+ T cells were upregulated in EBVaGC tumors and stromal tissue compared to non-EBVaGC.

conclusionsThe incidence of surgically resected EBVaGC at our center was 4%. EBVaGC tumors harbor elevated levels of TILs, including memory subtypes, within both tumor and tumor-related stroma. Robust TIL presence and upregulated PD-L1 positivity in EBVaGC may portend promising responses to immunotherapy agents. Further investigation into routine EBV testing and TIL phenotype of patients with gastric cancer to predict response to immunotherapy may be warranted.

Indexed as

Epstein-Barr Virus InfectionsStomach NeoplasmsB7-H1 AntigenBiomarkersHerpesvirus 4, HumanHumansB7-H1 AntigenBiomarkersEpstein–Barr virusGastric cancerImmunotherapyTumor-infiltrating lymphocytes

Identifiers

PMID38368775
PMCPMC10947842
OpenAlexW4391895563

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.